Drug delivery systems for the next generation of therapeutics
Although small molecule therapeutics still account for 90% of approved medicines, patient expectations are increasingly driving the industry towards targeted, precision treatments and new therapeutic modalities, which often require sophisticated delivery technologies to be effective medicines.
ELRIG are partnering with the European Technology Platform on Nanomedicine (ETPN), British Society for Nanomedicine and the University of Liverpool at Nanomed Europe #NME23.
With representatives from big pharma and biotech the ELRIG session will concentrate on the challenges of R&D in nanomedicines from an industry perspective. Covering a range of modalities, it will explore how drug dendrimer conjugates can improve the properties of small molecule therapeutics, discuss developing a lipid nanoparticle drug delivery platform for distinct diseases and report progress in the targeted delivery of exosomes.
Venue:
Teaching Hub502 & Guild of Students
Location: University Campus, Mount Pleasant Liverpool
Country: United Kingdom
Organiser Contact Details:
ELRIG UKT:
0044 1904 405177info@elrig.org
